Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low Following Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) hit a new 52-week low during mid-day trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to $1,000.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $618.51 and last traded at $630.08, with a volume of 111538 shares traded. The stock had previously closed at $637.36.

A number of other equities analysts have also issued reports on the stock. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Bank of America reaffirmed an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Citigroup lowered their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $966.88.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $25,000. Rakuten Securities Inc. increased its stake in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Finally, Avalon Trust Co bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

The company’s fifty day moving average price is $681.52 and its two-hundred day moving average price is $788.06. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $67.45 billion, a price-to-earnings ratio of 16.12, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the business earned $11.86 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.57%. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.